New York, N.Y.-based eClinical company Medidata Solutions inked a multi-year contract with Copenhagen-based pharmaceutical firm H. Lundbeck to manage more than 10 psychiatric phase II through IV trials. The studies will use Medidata Rave 5.6, set to launch this month. H. Lundbeck stated it chose Medidata’s electronic data capture (EDC) system based on feedback from clinical research associates and site managers.
“More and more, Medidata Rave is serving as the ‘backbone’ of the clinical research process – and we are pleased Lundbeck will benefit from Rave’s ability to easily integrate with other systems, meet the requirements of both large-and-small scale studies and enable them to rapidly conduct multiple studies in their strategic area of research,” said Tarek Sherif, chief executive officer of Medidata Solutions.
Recently, Boston-based electronic patient reported outcomes provider PHT announced it has integrated its LogPad ePRO system with Medidata Rave’s EDC technology. The companies have landed a deal with Sucampo Pharmaceuticals to manage its pediatric studies for the treatment of gastrointestinal disorders.The trial will enroll 120 patients throughout the U.S.
"By integrating multiple data streams, sponsors are able to take advantage of real efficiencies gained by using reliable electronic systems," said Phil Lee, president and chief executive officer of PHT.